A research agenda for assessing the potential contribution of genomic medicine to tobacco control

Tobacco Control

Volumn 16, Issue 1, 2007, Pages 53-58

  Hall, Wayne D ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ARTICLE; CHILD; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOMICS; HUMAN; MASS SCREENING; METHODOLOGY; PHARMACOGENETICS; PREVENTIVE MEDICINE; RESEARCH; SMOKING; SMOKING CESSATION;

ADOLESCENT; CHILD; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; MASS SCREENING; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PREVENTIVE MEDICINE; RESEARCH; SMOKING; SMOKING CESSATION;

EID: 33847669177     PISSN: 09644563     EISSN: None     Source Type: Journal    
DOI: 10.1136/tc.2006.016303     Document Type: Article

References (80)

1. Collins FS. Shattuck lecture-medical and societal consequences of the Human Genome Project. N Engl J Med 1999;341:28-37.
2. Collins FS, Green ED, Guttmacher A, et al. A vision for the future of genomics research. Nature 2003;422:835-47.
3. Lee AM, Tyndale RF. Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment. J Psychopharmacol 2006;20:7-14.
4. Sherman W. Test targets addiction gene. New York Daily News 12 Feb, 2006:28.
5. Lerman C, Berrettini W. Elucidating the role of genetic factors in smoking behavior and nicotine dependence. Am J Med Genef 2003;1188:48-54.
6. True WR, Heath AC, Scherrer if, et al. Genetic and environmental contributions to smoking. Addiction 1997;92:1277-87.
7. Hall WD, Madden P, Lynskey M. The genetics of tobacco use: methods, findings and policy implications. Tob Control 2002;11:119-24.
8. Pianezza ML, Sellers EM, Tyndole RF. Nicotine metabolism defect reduces smoking. Nature 1998;393:750.
9. Batra A, Gelfort G, Bartels M, et al. The dopamine D2 receptor (DRD2) gene - a genetic risk factor in heavy smoking? Addict Biol 2000;5:429-36.
10. Lerman C, Shields PG, Wileyto EP, et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 2003;22:541-8.
11. Munafo M, Johnstone E, Murphy M, et al. New directions in the genetic mechanisms underlying nicotine addiction. Addict Biol 2001;6:109-17.
12. Walton R, Johnstone E, Munafo M, et al. Genetic clues to the molecular basis of tobacco addiction and progress towards personalized therapy. Trends Mol Med 2001;7:70-6.
13. Lerman C, Swan GE. Non-replication of genetic association studies: is DAT all, folks? Nicotine Tob Res 2002;4:247-9.
14. Merikangas KR, Risch N. Genomic priorities and public health. Science 2003;302:599-601.
15. Goldman D, Oroszi G, Ducci F. The genetics of addictions: uncovering the genes. Nat Rev Genet 2005;6:521-32.
16. International HapMap Consortium. A haplolype map of the human genome. Nature 2005;437:1299-320.
17. Crabbe JC. Genetic contributions to addiction. Annu Rev Psychol 2002;53:435-62.
18. Uhl GR, Liu QR, Naiman D. Substance abuse vulnerability loci: converging genome scanning data. Trends Genet 2002;18:420-5.
19. Ioannidis JP, Trikalinos TA, Ntzani EE, et al. Genetic associations in large versus small studies: an empirical assessment, Lancet 2003;361:567-71.
20. Ioannidis JP. Genetic associations: false or true? Trends Mol Med 2003;9:135-8.
21. Fogerstrom KO. Nicotine-replacement therapies. In: Ferrence R, Slade J, Room R, et al, eds. Nicotine and public health. Washington, DC: American Public Health Association, 2000:199-207.
22. Balfour DJ. The neurobiology of tobacco dependence: a commentary. Respiration 2002;69:7-11.
23. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2002;(1):CD000031.
24. Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2001;(3):CD000146.
25. Song F, Raftery J, Aveyard P, et al. Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis. Med Decis Making 2002;22:S26-37.
26. Henningfield JE, Fant RV, Buchhalter AR, et al. Pharmacotherapy for nicotine dependence. CA Cancer J Clin 2005;55:281-99; quiz 322-3, 325.
27. Munafo M, Shields AE, Berrettini W, et al. Pharmacogenetics and nicotine addiction treatment. Future Pharmacogenomics 2005;6:211-23.
28. Flowers CR, Veenstra D. The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics 2004;22:481-93.
29. Marteau TM, Weinman J. Self-regulation and the behavioural response to DNA risk information: a theoretical analysis and framework for future research. Soc Sci Med 2006;62:1360-8.
30. Nelkin D, Lindee MS. The DNA mystique: the gene as a cultural icon. New York: Freeman, 1995.
31. Marteau TM, Croyle RT. The new genetics: psychological responses to genetic testing. BMJ 1998;316:693-6.
32. Marteau TM, Lerman C. Genetic risk and behavioural change. BMJ 2001;322:1056-9.
33. Capella JN, Lerman C, Romantan A, et al. News about genetics and smoking: priming, smoking history and news story believability on inferences of genetic susceptibility to tobacco addiction. Communie Res 2005;32:478-502.
34. Wright AJ, Weinman J, Marteau TM. The impact of learning of a genetic predisposition to nicotine dependence: an analogue study. Tob Control 2003;12:227-30.
35. Lindblom N, de Villiers SH, Kalayanov G, et al. Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration 2002;69:254-60.
36. Pentel P, Malin D. A vaccine for nicotine dependence: targeting the drug rather than the brain. Respiration 2002;69:193-7.
37. Vocci FJ, Chiang CN. Vaccines against nicotine: how effective are they likely to be in preventing smoking? CNS Drugs 2001;15:505-14.
38. de Villiers SH, Lindblom N, Kalayanov G, et al. Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell. Respiration 2002;69:247-53.
39. Hieda Y, Keyler DE, Ennifar S, et al. Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol 2000;22:809-19.
40. Pentel PR, Malin DH, Ennifar S, et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 2000;65:191-8.
41. Picciotto MR. Common aspects of the action of nicotine and other drugs of abuse. Drug Alcohol Depend 1998;51:165-72.
42. Cerny T. Anti-nicotine vaccination: where are we? Recent Results Cancer Res 2005;166:167-75.
43. Maurer P, Jennings GT, Willers J, et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicity. Eur J Immunol 2005;35:2031-40.
44. Cytos Biotechnology. Vaccine to treat nicotine addiction achieves proof of efficacy in phase II clinical trial, 14 May 2005. http://www.cytos.com/doc/Cytos_Press_E_050514.pdf (accessed 24 Oct 2006).
45. Nabi Biopharmaceuticals. Nabi Biopharmaceuticals receives NIDA grant to fund NicVAX development, 2005.hltp://phx.corporate-ir.net/phoenix. zhtml?c=100445&p = irol-newsArticle&ID=755463 (accessed 24 Oct 2006).
46. Xenova Group. Anti-smoking vaccine TA-NIC preliminary 12-month clinical trial results, 2005.http://www.xenova.co.uk/PressReleases/ pr_20050303_02.html (accessed 24 Oct 2006).
47. Hall WD. The prospects for immunotherapy in smoking cessation. Lancet 2002;360:1089-91.
48. Kosten TR, Rosen M, Bond J, et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 2002;20:1196- 204.
49. Leask JA, Chapman S. An attempt to swindle nature: press anti-immunisation reportage 1993-1997. Aust N Z J Public Health 1998;22:17-26.
50. Horton R. MMR science and fiction: exploring the vaccine crisis. London: Granta Books, 2004.
51. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56-63.
52. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296:47-55.
53. Cohen C, Kodas E, Griebel G. CB1 receptor antagonists for the treatment of nicotine addiction. Pharmacol Biochem Senov2005;81: 387-95.
54. Walley T, Haycox A, Boland A. Pharmacoeconomics. Edinburgh: Churchill Livingstone, 2004.
55. Hill S, Henry D. National medicinal drug policies: their relationship to pharmacoepidemiology. In: Strom BL, eds. Pharmacoepidemiology. 3rd edn. Chichester: Wiley, 2000:433-47.
56. Hall WD. Will nicotine genetics and a nicotine vaccine prevent cigarette smoking and smoking-related diseases? Plos Med 2005;2:860-3.
57. Holtzman NA, Marteau TM. Will genetics revolutionize medicine? N Engl J Med 2000;343:141-4.
58. Young RM, Lawford BR, Nutting A, et al. Advances in molecular genetics and the prevention and treatment of substance misuse: implications of association studies of the Al allele of the D2 dopamine receptor gene. Addict Behav 2004;29:1275-94.
59. Evans JP, Skrzynia C, Burke W. The complexities of predictive genetic testing. BMJ 2001;322:1052-6.
60. Khoury MJ, Yang Q, Gwinn M, et al. An epidemiologic assessment of genomic profiling for measuring susceptibility to common diseases and targeting interventions. Genet Med 2004;6:38-47.
61. Pharoah PD, Antoniou A, Bobrow M, et al. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002;31:33-6.
62. Holtzman NA, Shapiro D. Genetic testing and public policy. BMJ 1998;316:852-6.
63. Vineis P, Schulte P, McMichael AJ. Misconceptions about the use of genetic tests in populations. Lancet 2001;357:709-12.
64. Higashi MK, Veenstra DL. Managed care in the genomics era: assessing the cost effectiveness of genetic tests. Am J Manage Care 2003;9:493-500.
65. Yang Q, Khoury MJ, Botto L, et al. Improving the prediction of complex diseases by testing for multiple disease-susceptibility genes. Am J Med Genet 2003,72:636-49.
66. Khoury MJ, McCabe LL, McCabe ER. Population screening in the age of genomic medicine. N Engl J Med 2003;348:50-8.
67. Noble EP. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet B Neuropsychiatr Genet 2003;116:103-25.
68. Jonsson S, Thorsteinsdottir U, Gudbjartsson DF, et al. Familial risk of lung carcinoma in the Icelandic population. JAMA 2004;292:2977-83.
69. Czene K, Lichtenstein P, Hemminki K. Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish Family-Cancer Database Int J Cancer 2002;99:260-6.
70. Hemminki K, Lonnstedt I, Vaittinen P, et al. Estimation of genetic and environmental components in colorectal and lung cancer and melanoma. Genet Epidemiol 2001;20:107-16.
71. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000;343:78-85.
72. Risch N. The genetic epidemiology of cancer: interpreting family and twin studies and their implications for molecular genetic approaches. Cancer Epidemiol Biomarkers Prev 2001;10:733-41.
73. Humphries SE, Talmud PJ, Hawe E, et al. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet 2001;358:115-19.
74. Lomas DA, Silverman EK. The genetics of chronic obstructive pulmonary disease. Respir Res 2001;2:20-6.
75. Wang XL, Mahaney MC. Genotype-specific effects of smoking on risk of CHD. Lancet 2001;358:87-8.
76. Cohen PJ. Immunization for prevention and treatment of cocaine abuse: legal and ethical implications. Drug Alcohol Depend 1997;48:167-74.
77. Hasman A, Holm S. Nicotine conjugate vaccine: is there a right to a smoking future? J Med Ethics 2004;30:344-5.
78. Chaloupka FJ, Wakefield M, Czart C. Taxing tobacco: the impact of tobacco taxes on cigarette smoking and other tobacco use. In: Rabin RL, Sugarman SD, eds. Regulating tobacco. Oxford: Oxford University Press, 2001:39-71.
79. Rabin RL, Sugarman SD, eds. Regulating tobacco. Oxford: Oxford University Press, 2001.
80. Caron L, Karkazis K, Raffin TA, et al. Nicotine addiction through a neurogenomic prism: ethics, public health, and smoking. Nicotine Tob Res 2005,7:181-97.